Search results for "Ntic"

showing 10 items of 6004 documents

Anatomic site evaluation of the palatal bone for temporary orthodontic anchorage devices.

2008

: Objectives: The aim of the present study was to assess the micromorphologic characteristics of the palatal bone from an implantologic standpoint. Materials and Methods: The material consisted of tissue blocks of autopsy material from 22 subjects (18 males, three females) between 18 and 63 years of age. The specimens comprised the anterior median palatal region from 5 to 10 mm behind the incisive foramen. They were prepared in the transversal plane according to ground thin-section technology. The midpalatal area as well as an area of 3 mm bilateral to the midline were assessed, and a classification of quantitative palatal bone availability was developed. Results: The findings could be divi…

AdultMalePalate HardBone densityAdolescentDentistryAnatomic SiteSuture (anatomy)Orthodontic AppliancesCadaverBone DensityCadaverOrthodontic Anchorage ProceduresMedicineHumansIncisive foramenAgedOrthodonticsbusiness.industryDental Implantation EndosseousMiddle AgedClassificationTrabecular bonemedicine.anatomical_structureCompact boneCortical boneFemaleOral SurgerybusinessClinical oral implants research
researchProduct

Bone quality in the midpalate for temporary anchorage devices.

2009

Objective The aim of the present study was to quantitatively assess the bone quality of the palatal bone from an implantologic standpoint. Material and methods The material consisted of palatal tissue blocks of autopsy material from 22 subjects (19 male, three female), between 18 and 63 years of age. The specimens comprised the anterior part of median palate (APMP) from about 7 mm behind the incisive foramen (first premolar regions), the middle part of median palate (MPMP, second premolar region), and the posterior part of the median palate (PPMP, first molar region). They were prepared in the transversal plane using ground-thin-section technology. The midpalatal areas of the different part…

AdultMalePalate HardYounger ageBone densityAdolescentDentistryHard tissueMandibular first molarYoung AdultBone DensityBone Marrowparasitic diseasesBone qualityPremolarmedicineCadaverOrthodontic Anchorage ProceduresHumansIncisive foramenDental Implantsbusiness.industryAge FactorsCranial SuturesMiddle Agedmedicine.anatomical_structureFemaleOral SurgerybusinessBone volumeClinical oral implants research
researchProduct

Subregional Pathology of the Amygdala Complex and Entorhinal Region in Surgical Specimens From Patients With Pharmacoresistant Temporal Lobe Epilepsy

2000

The hippocampus, amygdala complex, and entorhinal region represent anatomically linked limbic structures of the mesiotemporal lobe. Chronic seizures and mnestic deficits in patients with pharmacoresistant mesial temporal lobe epilepsy (TLE) appear to correlate with distinct patterns of histopathological alterations in these areas. The complex anatomical organization of the amygdala and entorhinal region, however, render a detailed neuropathological evaluation of surgical specimens difficult. In this study, we present a combined cytoarchitectonical, pigmentarchitectonical, myelinarchitectonical, and immunohistochemical reconstruction of the amygdala, entorhinal region, and hippocampus from s…

AdultMalePathologymedicine.medical_specialtyAdolescentDrug ResistanceHippocampusAutopsyAmygdalaPathology and Forensic MedicineTemporal lobeCentral nervous system diseaseCellular and Molecular NeuroscienceEpilepsyBasal (phylogenetics)medicineEntorhinal CortexHumansGliosisSclerosisGeneral MedicineMiddle AgedAmygdalamedicine.diseaseTemporal LobeLobemedicine.anatomical_structureEpilepsy Temporal Lobenervous systemNeurologyChild PreschoolAnticonvulsantsFemaleNeurology (clinical)Psychologypsychological phenomena and processesJournal of Neuropathology & Experimental Neurology
researchProduct

Eosinophilic Meningitis due toAngiostrongylus cantonensisin Germany

2009

We report a case of eosinophilic meningitis due to Angiostrongylus cantonensis in a patient who returned from Thailand. The presence of a compatible epidemiologic history and eosinophilia in cerebrospinal fluid (CSF) lead to the diagnosis, which was confirmed by detection of specific antibodies. After treatment with albendazole and corticosteroids he recovered completely.

AdultMalePathologymedicine.medical_specialtyEosinophilic MeningitisBlotting WesternAlbendazoleAlbendazoleCerebrospinal fluidAdrenal Cortex HormonesGermanyEosinophiliamedicineAnimalsHumansEosinophiliaHelminthsMeningitisCerebrospinal FluidStrongylida InfectionsAnthelminticsTravelbiologybusiness.industryAngiostrongylus cantonensisGeneral MedicineThailandbiology.organism_classificationmedicine.diseaseAngiostrongylus cantonensisSpecific antibodyImmunologymedicine.symptombusinessMeningitismedicine.drugJournal of Travel Medicine
researchProduct

Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in pati…

2012

Summary Von Willebrand disease (VWD) is an inherited bleeding disorder caused by the quantitative or qualitative deficiency of von Willebrand factor (VWF). Replacement therapy with plasma-derived VWF/factor VIII (FVIII) concentrates is required in patients unresponsive to desmopressin. To assess the efficacy, safety and ease of use of a new, volume-reduced (VR) formulation of VWF/FVIII concentrate Haemate® P in patients requiring treatment for bleeding or prophylaxis for recurrent bleeding or for invasive procedures. Pharmacoeconomic variables were also recorded. Data were analysed using descriptive statistics. This was a multicentre, prospective, observational study. Consecutively enrolled…

AdultMalePediatricsmedicine.medical_specialtyAdolescentBlood Loss SurgicalSevere diseaseHemorrhageSettore MED/15 - Malattie Del SangueYoung AdultVon Willebrand factorCost of Illnesshemic and lymphatic diseaseshemophiliavon Willebrand FactorVon Willebrand diseasemedicineHumansIn patientProspective StudiesDesmopressinAdverse effectChildGenetics (clinical)AgedFactor VIIIbiologybusiness.industryDrug SubstitutionAnticoagulantsHematologyGeneral MedicineMiddle Agedmedicine.diseaseResponse to treatmentHospitalizationvon Willebrand DiseasesItalyChild Preschoolbiology.proteinPasteurizationObservational studyFemalebusinessmedicine.drug
researchProduct

Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study

2009

Summary Purpose To report on the first multicenter Italian experience with zonisamide as an add-on drug for refractory generalised or partial epilepsy in children, adolescents and young adults. Methods The patients were enrolled in a prospective, add-on, open-label treatment study from eight Italian centres for children and adolescent epilepsy care. Eighty-two young patients (45 males, 37 females), aged between 3 and 34 years (mean 13.1 years), all affected by partial (47) or generalised (35) refractory epilepsy, were enrolled in the study. ZNS was added to the baseline therapy at a starting dose of 1 mg/kg/day twice daily. This dose was increased by 2 mg/kg every 1–2 weeks over a period of…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentAntiepileptic drugsZonisamideIrritabilityStatistics NonparametricEpilepsyYoung AdultRefractorymedicineHumansNonparametricYoung adultAdverse effectPreschoolChildNeurologic ExaminationEpilepsybusiness.industryStatisticsElectroencephalographyDrug ToleranceIsoxazolesmedicine.diseaseMagnetic Resonance ImagingSettore MED/39 - Neuropsichiatria InfantileEpilepsy; Zonisamide; Pediatric epilepsy; Antiepileptic drugsAnticonvulsantTolerabilityNeurologyItalyZonisamideChild PreschoolAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessPediatric epilepsyAntiepileptic drugs; Epilepsy; Pediatric epilepsy; Zonisamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Tolerance; Electroencephalography; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Italy; Magnetic Resonance Imaging; Male; Neurologic Examination; Statistics Nonparametric; Young Adult; Neurology; Neurology (clinical)medicine.drugFollow-Up Studies
researchProduct

Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy

2004

Purpose: To evaluate the efficacy and safety of levetiracetam (LEV) in refractory crypto/symptomatic, partial or generalised epilepsy in children, adolescents and young adults. Methods: We performed a prospective open label add-on study in 99 patients (age 12 months to 32 years, mean 14 years) with partial or generalised, crypto/symtpomatic seizures. Levetiracetam was added to no more than two baseline AEDs and the efficacy was rated according to seizure type and frequency. Results: LEV was initiated at the starting dose of 10 mg/kg/day with 5-day increments up to 50 mg/kg/day, unless it was not tolerated. Concomitant therapy was generally not modified throughout the study. After a mean fol…

AdultMalePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentlevetiracetamefficacyIrritabilityStatistics NonparametricEpilepsyDOUBLE-BLINDantiepileptic drugmedicineHumansprospective trialProspective StudiesChildAdverse effectChi-Square DistributionEpilepsybusiness.industryInfantmedicine.diseasePiracetamAnticonvulsantNeurologyTolerabilityEpilepsy in childrenChild PreschoolAnesthesiaEpilepsy syndromesFemaleTRIALNeurology (clinical)Levetiracetammedicine.symptomtolerability PARTIAL SEIZURESbusinessFollow-Up Studiesmedicine.drug
researchProduct

Rufinamide in refractory childhood epileptic encephalopathies other than Lennox-Gastaut syndrome

2011

Background:  To report on the first multicenter Italian experience with rufinamide as adjunctive drug in children, adolescents and young adults with refractory childhood-onset epileptic encephalopathies other than Lennox-Gastaut syndrome. Methods:  Thirty-eight patients (19 males, 19 females), aged between 4 and 34 (mean 13.7 ± 8.3, median 12.5), all affected by different types of childhood-onset refractory epileptic encephalopathies other than Lennox-Gastaut syndrome, were treated with rufinamide as adjunctive drug for a mean period of 11.4 months (range 3-26 months). Results:  Fifteen of 38 patients (39.5%) had a ≥50% seizure reduction in co…

AdultMalePediatricsmedicine.medical_specialtyAdolescentrufinamideRufinamideIrritabilityrefractory seizures; rufinamide; epileptic encephalopathies-childhoodYoung AdultRefractoryepileptic encephalopathies-childhoodrefractory seizuresrufinamideMedicineHumansYoung adultAdverse effectChildPreschoolepileptic encephalopathies-childhoodBrain DiseasesEpilepsybusiness.industryEpileptic encephalopathies-childhood; Refractory seizures; RufinamideTriazolesmedicine.diseaseSettore MED/39 - Neuropsichiatria Infantilerefractory seizuresMigraineepileptic encephalopathies-childhood refractory seizures rufinamideNeurologyAnesthesiaChild PreschoolVomitingAnticonvulsantsFemaleNeurology (clinical)medicine.symptombusinessEpileptic encephalopathies-childhood; Refractory seizures; Rufinamide; Adolescent; Adult; Anticonvulsants; Brain Diseases; Child; Child Preschool; Epilepsy; Female; Humans; Male; Triazoles; Young Adult; Neurology (clinical); NeurologyLennox–Gastaut syndromemedicine.drug
researchProduct

Latvian registry of familial hypercholesterolemia: The first report of three-year results.

2018

Abstract Background and aims Familial hypercholesterolemia (FH) was rarely diagnosed in Latvia before 2015, when the Latvian Registry of FH (LRFH) was established. Here, we report the first experience of the LRFH over three years (2015–2017). Methods The LRFH is an ongoing nationwide, dynamic, long-term prospective cohort. The diagnosis of FH was assessed using the Dutch Lipid Clinic Network (DLCN) criteria. Cascade screening of first-degree relatives using age- and sex-specific percentiles of low-density lipoprotein cholesterol (LDL-C) was performed in relatives of patients with definite and probable FH. Results Among the 416 individuals included in the LRFH, 181 patients were diagnosed wi…

AdultMalePediatricsmedicine.medical_specialtyStatinHeredityTime Factorsmedicine.drug_classDown-RegulationCascade screeningFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansGenetic Predisposition to Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyLipid clinicLipoprotein cholesterolAgedbusiness.industryAnticholesteremic AgentsMean ageCholesterol LDLMiddle Agedmedicine.diseaseLatviaCoronary heart diseasePedigreePhenotypeTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersAtherosclerosis
researchProduct

Immunonephelometric determination of the C4b-binding protein.

1993

A fully mechanised immunonephelometric method for the rapid and specific determination of C4b-binding protein (C4b-BP) in citrated plasma is described. The method utilizes commercially available rabbit antiserum against human C4b-BP and a nephelometer analyser. A single determination can be performed within 6 min, requiring 80 microliters sample volume. The measuring range is about 10 to 200% of normal C4b-BP. Precision is characterized by intraassay coefficients of variation between 1.5% and 2.8%, and interassay coefficients of variation between 4.0% and 4.6% for the same C4b-BP concentrations. The nephelometry of C4b-BP was correlated with electroimmunodiffusion (Laurell technique; r = 0.…

AdultMalePercentileImmunodiffusionAnalytical chemistryAdministration Oralchemical and pharmacologic phenomenaFibrinogenRabbit antiserumNephelometry and TurbidimetryBlood plasmamedicineComplement C4bHumansAgedGlycoproteinsInflammationComplement Inactivator ProteinsChromatographyChemistryC4b-binding proteinHeparinHealthy subjectsAnticoagulantsHematologyMiddle AgedEvaluation Studies as TopicFemaleCarrier ProteinsQuantitative analysis (chemistry)Nephelometrymedicine.drugThrombosis research
researchProduct